Lancet Gastroenterology & Hepatology

Papers
(The H4-Index of Lancet Gastroenterology & Hepatology is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
GORD: pain, PPIs, and preciseness1873
Viral hepatitis: time for action620
Nationwide practice change after early termination of a randomised trial of laparoscopic pancreatoduodenectomy579
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply506
Lucky: Learning to Live Again498
EASL Congress 2024435
Treatment withdrawal in Crohn's disease: slowly becoming clearer419
Trends in alcohol-specific deaths in the UK and industry responses412
Research in Brief343
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design285
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma284
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled272
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship259
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11256
Voices from the frontline: how global funding cuts are reshaping the viral hepatitis response251
Developing policy for steatotic liver disease: an even better buy?240
Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30222
Thanks to our peer reviewers and contributors215
Appendicectomy: a disease-modifying treatment for ulcerative colitis?214
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium214
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial214
Global multi-stakeholder endorsement of the MAFLD definition208
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension206
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study194
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial184
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial179
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement173
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t164
ACG 2024159
Long-term VEDOKIDS results: implications for practice and research156
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47155
Management of portal vein thrombosis in cirrhosis138
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply138
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere135
Endoscopist deskilling: an unintended consequence of AI-assisted colonoscopy?132
Water and sanitation for all132
Research in Brief127
Idiopathic gastroparesis consensus misses the patient's voice127
Uptick of food allergies in recent years—real or epiphenomenon?126
Has the time come for a systematic top-down approach in Crohn's disease?126
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply124
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis120
Local and systemic therapy in liver cancer: the quest for synergy119
The potential of ctDNA in locoregional therapies for colorectal cancer119
All roads lead to the gut–brain microbiome network118
Bringing organ preservation closer for selected patients with rectal cancer117
Rare cause of dysphagia in a young woman116
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada115
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised p113
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial113
Availability of point-of-care HBV tests in resource-limited settings105
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)101
Resmetirom for NASH: balancing promise and prudence100
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study99
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study96
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review94
Sex and gender in inflammatory bowel disease outcomes and research93
Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial93
Lifting the minority tax in gastroenterology and hepatology92
The Year My Life Went Down the Toilet90
Management of malignant bowel obstruction – Authors' reply89
A women-focused matrix mentorship programme in gastroenterology89
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B86
Practicalities accessing precision medicine in biliary tract cancer84
Research in Brief82
Another arrow in the NASH quiver?81
18th Congress of the European Crohn's and Colitis Organisation80
An unusual complication after a variceal glue injection79
Britta Siegmund: answering the big questions in IBD78
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions78
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED77
Robotic versus laparoscopic surgery for middle and low rectal cancer76
Scientific and medical evidence informing expansion of hepatitis B treatment guidelines74
Managing inflammatory bowel disease: what to do when the best is unaffordable?74
0.76317119598389